Alexander Elias joined Centerview Partners in London in 2010 and has extensive experience advising companies on mergers and acquisitions, and other complex strategic issues primarily in the healthcare and life sciences sector.

Alexander has advised on numerous industry leading transactions including advising AstraZeneca on its $39 billion acquisition of Alexion, Teva on its $1.5 billion partnership with Sanofi for it’s anti- TL1A candidate duvakitug, and Nxera’s $0.5 billion acquisition of Idorsia’s Japan commercial stage portfolio. Alexander has advised on numerous biotech transactions including Neuroderm’s $1.1 billion sale to Mitsubishi Tanabe. Alexander also previously advised CSL on numerous transactions including their acquisition of Novartis’ influenza vaccine business.

Alexander has also advised on numerous transactions in the broader healthcare sector including advising on the $8 billion take private of Mediclinic PLC by a consortium of Remgro and MSC, Galenica on its $2 billion separation through IPO of Galenica Santé to form Vifor Pharma and the sale of ProPharma Group to Odyssey Investment Partners.

Alexander was formerly a healthcare private equity investor at Permira.

Alexander holds an M.A. in Philosophy, Politics and Economics from the University of Oxford.